Longevity company CEO Joe Betts-Lacroix reveals a disconnect between the FDA's stated goal of reducing animal models and its actual requirements. He states that in his company's interactions, the FDA has requested even more extensive animal studies, suggesting the move away from traditional preclinical testing is more rhetoric than reality.

Current drug development heavily relies on animal testing. However, significant biological differences mean we may be filtering out effective human medicines that fail in animal models, creating a hidden opportunity cost for medical breakthroughs.

The push away from animal models is a technical necessity, not just an ethical one. Advanced therapeutics like T-cell engagers and multispecific antibodies depend on human-specific biological pathways. These mechanisms are not accurately reproduced in animal models, rendering them ineffective for testing these new drug classes.

Despite hype around alternative methods, animal models will remain essential in drug development for the foreseeable future. The CEO argues that AI and ML will primarily make these studies more efficient by reducing the number of animals needed and improving data interpretation, not by eliminating the preclinical animal testing stage entirely.

The FDA's proposal to use non-animal models for first-in-human trials is a long-term scientific shift. However, competitors like Australia and China achieve faster trial starts now by simply streamlining existing regulatory processes, making them more attractive for biotech companies in the short-term.

With support from the FDA and NIH, the industry is moving to standardize organoid systems. This shift transforms them from niche research tools into reliable, quality-controlled preclinical models that can be used for personalized medicine and to generate more predictable drug discovery data.

The NIH will no longer award funding to new grant proposals that rely exclusively on animal models. This policy forces a shift towards New Approach Methodologies (NAMs), such as organoids and organ-on-chips, serving as a major catalyst for innovation and adoption in the preclinical testing space.

The FDA is eliminating mandatory animal testing because it's often misleading—90% of drugs passing animal studies fail in humans. The agency is embracing modern alternatives like computational modeling and organ-on-a-chip technology to get faster, more accurate safety data.

The FDA's proposed alternative to the Investigational New Drug (IND) pathway aims to speed up Phase 1 trials by leveraging existing preclinical data. A key detail suggests this may rely on validated non-animal methods (NAMS), potentially accelerating development for some drugs but also introducing uncertainty around regulatory acceptance of these newer technologies.